Results 51 to 60 of about 13,220 (219)

Acetylcysteine increases sensitivity of ceftazidime-avibactam–resistant enterobacterales with different enzymatic resistance to ceftazidime-avibactam in vitro and in vivo

BMC Microbiology, 2023
Abstract Background Ceftazidime-avibactam (CZA) improves treatment outcomes for infections caused by carbapenem-resistant organisms, but has led to serious bacterial resistance. Acetylcysteine (NAC) is an approved medication that protects the respiratory tract through antioxidant and anti-inflammatory effects.
Zeyu Huang, Yijia Han, Xiaotuan Zhang, Yao Sun, Yuzhan Lin, Luozhu Feng, Tieli Zhou, Zhongyong Wang   +7 more
openaire   +3 more sources

Correction to "Persistent <i>Burkholderia cepacia</i> Bacteremia in Reconstructive Surgery: Resistance to Ceftazidime/Avibactam and Co-Trimoxazole With Risk of Infective Endocarditis-A Case Report". [PDF]

Clin Case Rep
Clinical Case Reports, Volume 14, Issue 2, February 2026.
europepmc   +2 more sources

Activity of OP0595-β-lactam combination against Gram-negative bacteria with extended-spectrum, AmpC and carbapenem-hydrolysing β-lactama [PDF]

, 2015
Background: OP0595 is a diazabicyclooctane that (i) acts as a PBP2-ctive antibacterial, (ii) inhibits Class A and C β-lactamases and (iii), like mecillinam, gives β-lactamase-independent potentiation of β-lactams targeting other PBPs.
Livermore, David M., Mushtaq, Shazad, Warner, Marina, Woodford, Neil   +3 more
core   +1 more source

Management of KPC-Producing Klebsiella pneumoniae Infections [PDF]

, 2015
Klebsiella pneumoniae carbapenemase (KPC)-producing K. pneumoniae (KPC-KP) has become one of the most important contemporary pathogens, especially in endemic ...
M. Bassetti, D.R. Giacobbe, H. Giamarellou, C. Viscoli, G.L. Daikos, G. Dimopoulos, F.G. De Rosa, E.J. Giamarellos-Bourboulis, G.M. Rossolini, E. Righi, I. Karaiskos, M. Tumbarello, D.P. Nicolau, P.L. Viale, G. Poulakou, Rossolini, Munoz-Price, Grundmann, Maltezou, Giacobbe, Banerjee, Girmenia, Patel, Bauer, Arena, Kostrzewa, Rotova, Gaibani, Hoyos-Mallecot, Salimnia, Vincent, Arena, Paul, Zusman, Dickstein, Tzouvelekis, Tumbarello, Tumbarello, Daikos, Gutiérrez-Gutiérrez, Del Bono, Pea, Tenover, Clinical and Laboratory Standards Institute (CLSI), Nation, Capone, Monaco, Giacobbe, Giamarellou, Spyropoulou, Meletis, Karaiskos, Karaiskos, Sorlí, Sandri, Nation, Gonzalez-Padilla, Machuca, Stankowicz, Poulakou, Bassetti, Montravers, Bassetti, Ramirez, Wiskirchen, Giamarellou, Pontikis, Parker, Albiero, Lepak, Docobo-Pérez, Grabein, Shields, Temkin, Shields, Shields, Perez, Bulik, Giamarellou, Souli, Oliva, Cprek, Poulakou, Lu, Karvouniaris, Kollef, Rello, Solé-Lleonart, Palmer, Kalil, Monogue, Berthoin, Pea, Lorente, Ho, Kim, Keel, Martínez, Patel, Zarkotou, Falcone, Nguyen, de Oliveira, Dimopoulos, Chastre, Capellier, Havey, Matthaiou, Tacconelli, De Rosa, Sypsa, Gagliotti, Lin, Giacobbe, Munoz-Price, Tofteland, Schwaber, Lerner, De Rosa, Abdallah, Tumbarello, Giannella, Giannella, Giacobbe, Salsano, Sbrana, Girmenia, De Rosa, Forcina, Viale, Zuckerman, Saidel-Odes, Lübbert, Tascini, Oren, Tascini, Machuca, Bassetti, Falagas, Sutcliffe, Connors, Zhang, Solomkin   +142 more
core   +2 more sources

High-Level Ceftazidime/Avibactam Resistance in Escherichia coli Conferred by the Novel Plasmid-Mediated β-Lactamase Cmy-185 Variant [PDF]

, 2023
OBJECTIVES: To characterize a blaCMY variant associated with ceftazidime/avibactam resistance from a serially collected Escherichia coli isolate. METHODS: A patient with an intra-abdominal infection due to recurrent E.
Aitken, Samuel L, Bachman, William C, Bhatti, Micah M, Borjan, Jovan, Doi, Yohei, Egge, Stephanie L, Endres, Bradley T, Kawai, Akito, Khan, Ayesha, McElheny, Christi L, Miller, William R, Saharasbhojane, Pranoti, Shelburne, Samuel A, Shields, Ryan K, Shropshire, William C, Wu, Chin-Ting   +15 more
core   +2 more sources

Ceftazidime/Avibactam: Who Says You Can’t Teach an Old Drug New Tricks?

Journal of Pharmacy & Pharmaceutical Sciences, 2016
Purpose: Gram-negative resistance continues to rise with treatment options becoming more limited. Ceftazidime/avibactam was recently approved in the United States and Europe, which combines an established third-generation cephalosporin with a new, unique,
Katie E. Barber, Jessica K. Ortwine, Ronda L Akins   +2 more
doaj   +1 more source

Phase I Study Assessing the Pharmacokinetic Profile, Safety, and Tolerability of a Single Dose of Ceftazidime-Avibactam in Hospitalized Pediatric Patients. [PDF]

, 2016
This study aimed to investigate the pharmacokinetics (PK), safety, and tolerability of a single dose of ceftazidime-avibactam in pediatric patients. A phase I, multicenter, open-label PK study was conducted in pediatric patients hospitalized with an ...
Armstrong, Jon, Arrieta, Antonio, Bishai, Raafat, Bradley, John S, Das, Shampa, Delair, Shirley, Edeki, Timi, Holmes, William C, Li, Jianguo, Moffett, Kathryn S, Mukundan, Deepa, Perez, Norma, Romero, José R, Speicher, David, Sullivan, Janice E, Zhou, Diansong   +15 more
core  

Evaluation of FilmArray Multiplex PCR Test Results in Bloodstream Infections in Oncological Patients

Journal of Clinical Laboratory Analysis, EarlyView.
In this study conducted at an oncology hospital, BCID2 panel results for the rapid identification of microorganisms and resistance genes in positive blood culture samples were compared with conventional culture methods. The BCID2 panel provided faster results and showed a high correlation with traditional methods.
İpek Mumcuoğlu, Sevgi Şahin, Esra Tavukcu, Neşe İnan, Ayşe Semra Güreser, Serap Süzük Yıldız, Tuba Dal   +6 more
wiley   +1 more source

Development of Resistance to Eravacycline by Klebsiella pneumoniae and Collateral Sensitivity-Guided Design of Combination Therapies

Microbiology Spectrum, 2022
The evolution of bacterial antibiotic resistance is exhausting the list of currently used antibiotics and endangers those in the pipeline. The combination of antibiotics is a promising strategy that may suppress resistance development and/or achieve ...
Congjuan Xu, Xiaoya Wei, Yongxin Jin, Fang Bai, Zhihui Cheng, Shuiping Chen, Xiaolei Pan, Weihui Wu   +7 more
doaj   +1 more source

Reduced Ceftazidime-Avibactam Susceptibility in KPC-Producing Klebsiella pneumoniae From Patients Without Ceftazidime-Avibactam Use History – A Multicenter Study in China [PDF]

Frontiers in Microbiology, 2020
KPC-producing Klebsiella pneumoniae (KPC-KP) is the most widely spread carbapenem-resistant Enterobacteriaceae (CRE) in China. Avibactam is a novel non-β-lactam β-lactamase inhibitor which is highly active against KPC. Recently, ceftazidime-avibactam (CAZ-AVI) was approved for clinical treatment in China.
Xiaoyan Cui, Bin Shan, Xue Zhang, Fen Qu, Fen Qu, Wei Jia, Bin Huang, Hua Yu, Yi-Wei Tang, Yi-Wei Tang, Yi-Wei Tang, Liang Chen, Liang Chen, Hong Du   +13 more
openaire   +3 more sources